Clinical Trials Browser

Recruiting × Breast Neoplasms × durvalumab × Clear all

NCT01042379 2026-03-13

I-SPY

Phase 2 Recruiting

Pathologic Complete Response, Breast Neoplasms, Hemangiosarcoma, Neoplasms, Triple Negative Breast Neoplasms

NCT04711824 2025-12-23

SOLARA

Phase 1/2 Recruiting

Brain Neoplasms, Breast Neoplasms

NCT06954480 2025-11-19

DIAMOND

Phase 2 Recruiting

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT03740893 2025-08-11

PHOENIX

Phase 2 Recruiting

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT06508216 2024-07-22

COMPASS-TNBC

Phase 1/2 Recruiting

Breast Neoplasms, Neoplasm Metastasis, Triple Negative Breast Neoplasms

NCT05720260 2024-06-10

Immunotherapy, Hormone Therapy, and AKT Inhibitor for Premenopausal ER Positive MBC

Phase 2 Recruiting

Breast Neoplasms